Letrozole
Other / unclassified targets CYP19A1 via inhibition
Regulatory milestones approvals, filings & regulatory actions · 8 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansions (7) | US (FDA) | FEMARA | — | 2001-01-10 – 2010-04-30 | fda.gov ↗ |
| Approved | US (FDA) | FEMARA | — | 1997-07-25 | fda.gov ↗ |
Trials 451 · started per year
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 011 trials | ||||||
| Phase 0 | NCT05238831 | Jan 2023 → May 2026 | female breast carcinoma, ovarian carcinoma, pancreatic ductal adenocarcinoma, pancreatic large cell neuroendocrine carcinoma +2 | OHSU Knight Cancer Institute | Withdrawn | No outcome recorded |
| Phase 0 | NCT05157672 | Dec 2021 → Aug 2023 | — | Washington State University | Unknown | No outcome recorded |
| Phase 0 | NCT04361175 | Mar → Sep 2021 | infertility disorder | Assiut University | Unknown | No outcome recorded |
| Phase 0 | NCT04630210 | Feb 2021 → Jan 2025 | breast cancer | Universitaire Ziekenhuizen KU Leuven | Withdrawn | No outcome recorded |
| Phase 0 | NCT04130152 | Nov 2019 → Jan 2022 | breast cancer | SOLTI Breast Cancer Research Group | Completed | No outcome recorded |
| Phase 0 | NCT04049227 | Aug 2019 → Apr 2023 | endometrial endometrioid adenocarcinoma | Northwestern University | Completed | No outcome recorded |
| Phase 0 | NCT04102618 | Mar 2019 → Apr 2022 | breast cancer | Oncolytics Biotech | Terminated | No outcome recorded |
| Phase 0 | NCT03378297 | May 2018 → Jan 2023 | ovarian cancer | Haukeland University Hospital | Completed | No outcome recorded |
| Phase 0 | NCT03122197 | May 2017 → Sep 2027 expected | brain neoplasm | University of Cincinnati | Recruiting | No outcome recorded |
| Phase 0 | NCT02802748 | Jul 2016 → Jan 2018 | breast cancer | SOLTI Breast Cancer Research Group | Completed | No outcome recorded |
| Phase 0 | NCT00651976 | Mar 2008 → Sep 2018 | breast cancer | Vanderbilt-Ingram Cancer Center | Terminated | No outcome recorded |
| Phase 142 trials | ||||||
| Phase 1 | NCT07401381 | Jun 2026 → May 2028 expected | hormone receptor-positive breast cancer | Rovi Pharmaceuticals Laboratories | Recruiting | No outcome recorded |
| Phase 1 | NCT07604571 | May 2026 → Jun 2032 expected | hormone receptor-positive breast cancer | Novartis Pharmaceuticals | Recruiting | No outcome recorded |
| Phase 1 | NCT06139107 | Aug 2024 → Sep 2026 expected | breast cancer | Mridula George, MD | Recruiting | No outcome recorded |
| Phase 1 | NCT06813118 | Jun 2024 → Mar 2025 | polycystic ovary syndrome | HITEC-Institute of Medical Sciences | Completed | No outcome recorded |
| Phase 1 | NCT06253195 | Apr 2024 → Apr 2026 | hormone receptor-positive breast cancer, metastatic neoplasm | BeOne Medicines | Completed | No outcome recorded |
| Phase 1 | NCT06120283 | Dec 2023 → Nov 2028 expected | hormone receptor-positive breast cancer, non-small cell lung carcinoma | BeOne Medicines | Recruiting | No outcome recorded |
| Phase 1 | NCT06315205 | Jul 2023 → Mar 2026 overdue | — | Rovi Pharmaceuticals Laboratories | Active not recruiting | No outcome recorded |
| Phase 1 | NCT04316169 | Oct 2021 → Jan 2027 | female breast carcinoma | Medical College of Wisconsin | Withdrawn | No outcome recorded |
| Phase 1 | NCT04987632 | Aug 2021 → Dec 2022 | female infertility, polycystic ovary syndrome | Qiu-ping Lin | Unknown | No outcome recorded |
| Phase 1 | NCT05337657 | Jun 2021 → Dec 2023 | breast cancer | Genor Biopharma Co., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT04177693 | Nov 2020 → Jan 2022 | leiomyoma | Yale University | Completed | No outcome recorded |
| Phase 1 | NCT03554044 | Feb 2020 → Dec 2023 | Her2-receptor negative breast cancer, estrogen-receptor positive breast cancer, female breast carcinoma, invasive breast carcinoma | University of California, San Francisco | Completed | No outcome recorded |
| Phase 1 | NCT04188548 | Dec 2019 → Jun 2020 overdue | breast cancer, endometrial cancer | Eli Lilly and Company | Active not recruiting | No outcome recorded |
| Phase 1 | NCT06047184 | Jul 2019 → Oct 2023 | female breast carcinoma | BeBetter Med Inc | Unknown | No outcome recorded |
| Phase 1 | NCT03959891 | May 2019 → Dec 2022 overdue | breast cancer | Massachusetts General Hospital | Active not recruiting | No outcome recorded |
| Phase 1 | NCT03401320 | Nov 2017 → May 2024 | — | Rovi Pharmaceuticals Laboratories | Completed | No outcome recorded |
| Phase 1 | NCT03284723 | Nov 2017 → Aug 2021 | breast neoplasm | Pfizer | Terminated | No outcome recorded |
| Phase 1 | NCT03308201 | Oct 2017 → Jun 2022 | breast cancer | Tianjin Hemay Pharmaceutical Co., Ltd | Completed | No outcome recorded |
| Phase 1 | NCT03128619 | Aug 2017 → Mar 2022 | Her2-receptor negative breast cancer, estrogen-receptor positive breast cancer, invasive breast carcinoma, progesterone-receptor positive breast cancer | Jonsson Comprehensive Cancer Center | Terminated | No outcome recorded |
| Phase 1 | NCT03099174 | May 2017 → May 2023 | breast neoplasm | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT02619669 | Apr 2017 → Jun 2019 | female breast carcinoma | Gary Schwartz | Withdrawn | No outcome recorded |
| Phase 1 | NCT03006172 | Dec 2016 → Dec 2026 expected | breast cancer | Genentech, Inc. | Active not recruiting | No outcome recorded |
| Phase 1 | NCT02684032 | Jun 2016 → Jan 2022 | breast cancer | Celcuity Inc | Completed | No outcome recorded |
| Phase 1 | NCT02619162 | Jul 2015 → Nov 2017 | breast cancer | Spanish National Cancer Research Centre | Completed | No outcome recorded |
| Phase 1 | NCT02448459 | May 2015 → Mar 2016 | infertility disorder | University of Sao Paulo | Completed | No outcome recorded |
| Phase 1 | NCT02333370 | Feb 2015 → Sep 2022 | hormone receptor-positive breast cancer | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT02093351 | Sep 2014 → Apr 2015 | cancer | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT02152943 | Jul 2014 → Dec 2020 | HER2 positive breast carcinoma, hormone receptor-positive breast cancer | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT02154776 | Jun 2014 → Oct 2016 | breast cancer | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT02057133 | Mar 2014 → Mar 2021 overdue | breast neoplasm | Eli Lilly and Company | Active not recruiting | No outcome recorded |
| Phase 1 | NCT01870505 | May 2013 → Feb 2022 | female breast carcinoma | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT01791478 | Apr 2013 → Dec 2014 overdue | Her2-receptor negative breast cancer, estrogen-receptor positive breast cancer, female breast carcinoma, invasive ductal breast carcinoma +1 | Vanderbilt-Ingram Cancer Center | Active not recruiting | No outcome recorded |
| Phase 1 | NCT01693289 | Jan → Jun 2012 | — | Zagazig University | Completed | No outcome recorded |
| Phase 1 | NCT00945360 | Mar → May 2011 | uterine corpus leiomyoma | American University of Beirut Medical Center | Withdrawn | No outcome recorded |
| Phase 1 | NCT01248494 | Nov 2010 → Dec 2012 | breast cancer | Vanderbilt-Ingram Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT01208441 | Nov 2010 → Dec 2011 | Her2-receptor negative breast cancer, estrogen-receptor positive breast cancer, female breast carcinoma, progesterone-receptor positive breast cancer | National Cancer Institute (NCI) | Terminated | No outcome recorded |
| Phase 1 | NCT01077453 | Mar 2010 → Jun 2014 | lobular breast carcinoma in situ | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1 | NCT01372982 | Apr → Jun 2008 | — | Dr. Reddy's Laboratories Limited | Completed | No outcome recorded |
| Phase 1 | NCT01375452 | Mar → May 2008 | — | Dr. Reddy's Laboratories Limited | Completed | No outcome recorded |
| Phase 1 | NCT00648154 | Nov → Dec 2005 | — | Mylan Pharmaceuticals Inc | Completed | No outcome recorded |
| Phase 1 | NCT00648063 | Nov → Dec 2005 | — | Mylan Pharmaceuticals Inc | Completed | No outcome recorded |
| Phase 1 | NCT00006174 | Aug 2000 → May 2009 | McCune-Albright syndrome, polyostotic fibrous dysplasia, precocious puberty | National Institute of Dental and Craniofacial Research (NIDCR) | Completed | No outcome recorded |
| Phase 1/229 trials | ||||||
| Phase 1/2 | NCT07570966 | Jun 2026 → Aug 2031 | castration-resistant prostate carcinoma, hormone receptor-positive breast cancer | Novartis Pharmaceuticals | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT07389733 | Mar 2026 → Dec 2028 expected | breast cancer | Shandong Suncadia Medicine Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT07288359 | Dec 2025 → May 2031 expected | castration-resistant prostate carcinoma, hormone receptor-positive breast cancer | Novartis Pharmaceuticals | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06998407 | Aug 2025 → Aug 2028 expected | hormone receptor-positive breast cancer | Avenzo Therapeutics, Inc. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06706414 | Mar 2025 → Aug 2026 overdue | male infertility | Martin Blomberg Jensen | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT06555068 | Aug 2024 → Dec 2027 expected | breast cancer | Jiangsu HengRui Medicine Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05867251 | Aug 2023 → Jan 2028 expected | endometrial cancer, fallopian tube cancer, hormone receptor-positive breast cancer, malignant epithelial tumor of ovary +2 | Avenzo Therapeutics, Inc. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05705505 | Mar 2023 → Jan 2026 | endometrial endometrioid adenocarcinoma | Traws Pharma, Inc. | Unknown | No outcome recorded |
| Phase 1/2 | NCT05918718 | Jan 2023 → May 2024 | ectopic pregnancy | Tehran University of Medical Sciences | Unknown | No outcome recorded |
| Phase 1/2 | NCT05262400 | Mar 2022 → Aug 2026 overdue | breast cancer | Pfizer | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT04486352 | Oct 2021 → Oct 2026 expected | endometrial cancer | Alliance Foundation Trials, LLC. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT04282031 | Jun 2020 → Dec 2024 overdue | hormone receptor-positive breast cancer | Beta Pharma (Suzhou) Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT04215003 | Jan 2020 → Dec 2024 | breast cancer | Fudan University | Unknown | No outcome recorded |
| Phase 1/2 | NCT03913234 | Jun 2019 → Oct 2023 | HER2 positive breast carcinoma | Yonsei University | Unknown | No outcome recorded |
| Phase 1/2 | NCT03772353 | May 2019 → Jun 2023 | breast cancer | Fudan University | Unknown | No outcome recorded |
| Phase 1/2 | NCT04488107 | Feb 2019 → Dec 2021 | breast neoplasm | Ahon Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
| Phase 1/2 | NCT03709082 | Oct 2018 → Mar 2020 | HER2 positive breast carcinoma | University of Kansas Medical Center | Terminated | No outcome recorded |
| Phase 1/2 | NCT03424005 | Mar 2018 → Sep 2030 expected | breast cancer | Hoffmann-La Roche | Recruiting | No outcome recorded |
| Phase 1/2 | NCT03481998 | Mar 2018 → Jul 2022 | breast cancer | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 1/2 | NCT03519178 | Mar 2018 → Apr 2023 | breast cancer | Pfizer | Terminated | No outcome recorded |
| Phase 1/2 | NCT03054363 | Nov 2017 → Jan 2023 | breast cancer | University of Colorado, Denver | Completed | No outcome recorded |
| Phase 1/2 | NCT02562118 | Oct 2015 → Jan 2027 expected | breast cancer | National University Hospital, Singapore | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT02520063 | Feb 2015 → Dec 2022 | breast cancer | University of Alabama at Birmingham | Completed | No outcome recorded |
| Phase 1/2 | NCT01686828 | Jun 2013 → May 2015 | hypogonadism, obesity disorder, type 2 diabetes mellitus | University of Washington | Completed | No outcome recorded |
| Phase 1/2 | NCT01484041 | Apr 2012 → Dec 2015 | breast cancer | Georgetown University | Terminated | No outcome recorded |
| Phase 1/2 | NCT01105312 | Sep 2010 → Aug 2013 | breast cancer | Alliance for Clinical Trials in Oncology | Completed | No outcome recorded |
| Phase 1/2 | NCT00740194 | Aug → Dec 2008 | — | University Hospital, Ghent | Completed | No outcome recorded |
| Phase 1/2 | NCT00351416 | Jan 2004 → Jun 2009 | — | Massachusetts General Hospital | Unknown | No outcome recorded |
| Phase 1/2 | NCT00290745 | Feb 2002 → Jul 2009 | breast cancer | University of California, San Francisco | Completed | No outcome recorded |
| Phase 2191 trials | ||||||
| Phase 2 | NCT07394946 | Jun 2026 → Jul 2027 expected | hormone receptor-positive breast cancer | Cancer Care Hospital & Research Centre Foundation, Lahore | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07618923 | Jun 2026 → Jun 2028 expected | hormone receptor-positive breast cancer | Tang-Du Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07527806 | May 2026 → May 2029 expected | breast cancer | Peking University Cancer Hospital & Institute | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07483307 | Mar 2026 → Mar 2030 expected | Her2-receptor negative breast cancer, breast lobular carcinoma, estrogen-receptor positive breast cancer | Memorial Sloan Kettering Cancer Center | Recruiting | No outcome recorded |
| Phase 2 | NCT07305246 | Dec 2025 → Mar 2027 expected | breast cancer | First Hospital of China Medical University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07179939 | Sep 2025 → Dec 2030 expected | HER2 positive breast carcinoma | Fudan University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07054190 | Sep 2025 → Jul 2027 expected | breast cancer | Hoffmann-La Roche | Recruiting | No outcome recorded |
| Phase 2 | NCT06979596 | Aug 2025 → Nov 2027 expected | cancer | Merck Sharp & Dohme LLC | Recruiting | No outcome recorded |
| Phase 2 | NCT06970912 | Aug 2025 → Dec 2029 expected | female breast carcinoma, hormone receptor-positive breast cancer | Peking University People's Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT06953882 | Jul 2025 → Sep 2030 expected | Her2-receptor negative breast cancer | Yale University | Recruiting | No outcome recorded |
| Show all 191 trials opens the full record — a long page | ||||||
| Phase 2/317 trials | ||||||
| Phase 2/3 | NCT07319429 | Jan 2026 → Dec 2027 expected | endometrial cancer, infertility disorder | Fudan University | Recruiting | No outcome recorded |
| Phase 2/3 | NCT07669402 | Dec 2023 → Feb 2026 | oligoasthenoteratozoospermia | Tehran University of Medical Sciences | Completed | No outcome recorded |
| Phase 2/3 | NCT03458221 | Jan 2023 → Oct 2026 expected | ovarian cancer | Gynaecologisch Oncologisch Centrum Zuid | Recruiting | No outcome recorded |
| Phase 2/3 | NCT05454358 | Aug 2022 → Dec 2025 | endometrial cancer | Fudan University | Terminated | No outcome recorded |
| Phase 2/3 | NCT05316935 | Jul 2022 → Mar 2026 overdue | atypical endometrial hyperplasia, endometrium neoplasm, progesterone resistance | Xiaojun Chen | Recruiting | No outcome recorded |
| Phase 2/3 | NCT06379113 | Jul 2022 → Mar 2026 overdue | atypical endometrial hyperplasia, endometrium neoplasm, obesity disorder, progesterone resistance | Xiaojun Chen | Recruiting | No outcome recorded |
| Phase 2/3 | NCT06390904 | Jul 2022 → Jul 2025 overdue | atypical endometrial hyperplasia, obesity disorder, progesterone resistance | Xiaojun Chen | Active not recruiting | No outcome recorded |
| Phase 2/3 | NCT05203562 | Jun 2020 → Dec 2022 | gestational trophoblastic neoplasm | Zagazig University | Unknown | No outcome recorded |
| Phase 2/3 | NCT03373708 | Dec 2017 → Dec 2019 | breast cancer | Zhiyong Yu | Unknown | No outcome recorded |
| Phase 2/3 | NCT03507465 | Nov 2017 → Nov 2019 | breast cancer | Guangdong Provincial People's Hospital | Unknown | No outcome recorded |
| Phase 2/3 | NCT03285802 | Sep 2017 → Feb 2019 | uterine cancer | Greater Baltimore Medical Center | Completed | No outcome recorded |
| Phase 2/3 | NCT05702957 | Sep 2016 → Oct 2019 | female infertility, polycystic ovary syndrome | Services Institute of Medical Sciences, Pakistan | Completed | No outcome recorded |
| Phase 2/3 | NCT02692755 | Sep 2016 → Dec 2019 | hormone receptor-positive breast cancer | Georgetown University | Completed | No outcome recorded |
| Phase 2/3 | NCT02405156 | Mar 2015 → Dec 2016 | pregnancy disorder with abortive outcome | Ain Shams University | Completed | No outcome recorded |
| Phase 2/3 | NCT02221999 | Sep 2013 → Jan 2019 overdue | breast mucinous carcinoma, inflammatory breast carcinoma, invasive tubular breast carcinoma | RenJi Hospital | Active not recruiting | No outcome recorded |
| Phase 2/3 | NCT00333047 | Jul 2002 → ? | breast cancer | Novartis | Completed | No outcome recorded |
| Phase 2/3 | NCT00535418 | Jun 2000 → Jul 2002 | breast cancer | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 378 trials | ||||||
| Phase 3 | NCT07391774 | Feb 2027 → Jul 2029 expected | Her2-receptor negative breast cancer, estrogen-receptor positive breast cancer | National Cancer Institute (NCI) | Recruiting | No outcome recorded |
| Phase 3 | NCT07340658 | Aug 2026 → Feb 2029 expected | breast cancer | Rovi Pharmaceuticals Laboratories | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07153757 | Sep 2025 → Sep 2033 expected | female breast carcinoma | Fudan University | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06757634 | Jul 2025 → Mar 2029 expected | breast cancer | Celcuity Inc | Recruiting | No outcome recorded |
| Phase 3 | NCT07005557 | Jun 2025 → May 2030 expected | breast cancer | Fudan University | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06223698 | May 2025 → May 2032 expected | breast cancer | Region Örebro County | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06492616 | Sep 2024 → Aug 2029 expected | breast cancer | Stemline Therapeutics, Inc. | Recruiting | No outcome recorded |
| Phase 3 | NCT06507618 | Jul 2024 → Jun 2029 expected | female breast carcinoma | University of Virginia | Recruiting | No outcome recorded |
| Phase 3 | NCT06405243 | Jun → Dec 2024 | polycystic ovary syndrome | Beni-Suef University | Unknown | No outcome recorded |
| Phase 3 | NCT06418347 | Apr 2024 → Nov 2025 | female infertility, polycystic ovary syndrome | Ain Shams University | Unknown | No outcome recorded |
| Phase 3 | NCT06244745 | Dec 2023 → May 2025 overdue | ovarian cyst | IVI Madrid | Recruiting | No outcome recorded |
| Phase 3 | NCT06403488 | Oct 2023 → Jan 2024 | polycystic ovary syndrome | Beni-Suef University | Completed | No outcome recorded |
| Phase 3 | NCT07616973 | May 2023 → May 2026 overdue | female infertility | Sana'a University | Active not recruiting | No outcome recorded |
| Phase 3 | NCT07143682 | Jan 2023 → May 2024 | female infertility, polycystic ovary syndrome | Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh | Completed | No outcome recorded |
| Phase 3 | NCT05601700 | Sep 2022 → Sep 2029 expected | ovarian serous adenocarcinoma | Ente Ospedaliero Ospedali Galliera | Recruiting | No outcome recorded |
| Phase 3 | NCT05304273 | May 2022 → Jul 2024 | pregnancy disorder with abortive outcome | Calcutta National Medical College and Hospital | Completed | No outcome recorded |
| Phase 3 | NCT06313983 | Jan 2022 → Dec 2025 overdue | breast cancer | Tianjin Hemay Pharmaceutical Co., Ltd | Recruiting | No outcome recorded |
| Phase 3 | NCT05429684 | Jan 2021 → Feb 2024 | HER2 positive breast carcinoma | First Affiliated Hospital Xi'an Jiaotong University | Unknown | No outcome recorded |
| Phase 3 | NCT04341545 | Dec 2020 → Dec 2024 | tubal pregnancy | Queen Mary Hospital, Hong Kong | Unknown | No outcome recorded |
| Phase 3 | NCT04111978 | Nov 2020 → Jul 2027 expected | fallopian tube neoplasm, malignant ovarian serous tumor, ovarian endometrioid adenocarcinoma, peritoneal neoplasm | Swiss GO Trial Group | Recruiting | No outcome recorded |
| Phase 3 | NCT04421547 | Jun 2020 → Nov 2024 | malignant epithelial tumor of ovary | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | Terminated | No outcome recorded |
| Phase 3 | NCT04158362 | Jun 2020 → Apr 2025 overdue | metastatic malignant neoplasm | UNICANCER | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06486870 | Jan 2020 → Jan 2024 | polycystic ovary syndrome | Cairo University | Completed | No outcome recorded |
| Phase 3 | NCT04095364 | Sep 2019 → Feb 2027 expected | fallopian tube serous adenocarcinoma, ovarian serous adenocarcinoma, primary peritoneal serous adenocarcinoma | NRG Oncology | Active not recruiting | No outcome recorded |
| Phase 3 | NCT02912988 | Mar 2018 → Apr 2022 | infertility disorder | The University of Hong Kong | Completed | No outcome recorded |
| Phase 3 | NCT03439046 | Feb 2018 → Dec 2023 | breast cancer | Novartis Pharmaceuticals | Terminated | No outcome recorded |
| Phase 3 | NCT03664050 | Jan → Dec 2018 | ovarian hyperstimulation syndrome | Ain Shams University | Unknown | No outcome recorded |
| Phase 3 | NCT03135301 | Jun 2017 → Dec 2023 | female infertility | Assiut University | Unknown | No outcome recorded |
| Phase 3 | NCT03079011 | Mar 2017 → Apr 2021 | breast cancer | UNICANCER | Completed | No outcome recorded |
| Phase 3 | NCT02941926 | Nov 2016 → Nov 2019 | breast cancer | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT03096847 | Oct 2016 → Dec 2018 | breast cancer | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT03011684 | Jul 2016 → Mar 2028 expected | infertility disorder | University of California, San Francisco | Recruiting | No outcome recorded |
| Phase 3 | NCT02769104 | May 2016 → Jul 2018 | — | Zhejiang Cancer Hospital | Unknown | No outcome recorded |
| Phase 3 | NCT02600923 | Apr 2016 → May 2019 | female breast carcinoma | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT02730091 | Feb 2016 → Mar 2020 | breast cancer | Centre Hospitalier Universitaire de Besancon | Terminated | No outcome recorded |
| Phase 3 | NCT03241472 | Feb 2016 → May 2017 | infertility disorder | Assiut University | Completed | No outcome recorded |
| Phase 3 | NCT02344472 | Sep 2015 → Jan 2025 | breast cancer | University of Ulm | Unknown | No outcome recorded |
| Phase 3 | NCT02491320 | Aug 2015 → Oct 2019 | polycystic ovary syndrome | The First Affiliated Hospital of Guangzhou Medical University | Completed | No outcome recorded |
| Phase 3 | NCT02900105 | Feb 2015 → Mar 2017 | azoospermia, oligospermia | KK Women's and Children's Hospital | Completed | No outcome recorded |
| Phase 3 | NCT02732808 | Sep 2014 → Apr 2016 | female infertility | Royan Institute | Completed | No outcome recorded |
| Phase 3 | NCT01950182 | Sep 2013 → May 2020 | breast cancer | Sun Yat-sen University | Completed | No outcome recorded |
| Phase 3 | NCT02918084 | Jun 2013 → Jun 2028 expected | breast cancer | IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy | Active not recruiting | No outcome recorded |
| Phase 3 | NCT02980965 | May 2013 → Feb 2017 | female breast carcinoma | Fudan University | Completed | No outcome recorded |
| Phase 3 | NCT01758146 | Jan 2012 → Jan 2020 | breast cancer | Post Graduate Institute of Medical Education and Research, Chandigarh | Unknown | No outcome recorded |
| Phase 3 | NCT00908531 | May 2009 → Dec 2013 | female breast carcinoma | Danish Breast Cancer Cooperative Group | Terminated | No outcome recorded |
| Phase 3 | NCT00893061 | Mar 2009 → Apr 2012 | breast cancer | Centre Oscar Lambret | Completed | No outcome recorded |
| Phase 3 | NCT00949598 | Dec 2008 → Oct 2010 | breast cancer | Institut du Cancer de Montpellier - Val d'Aurelle | Completed | No outcome recorded |
| Phase 3 | NCT00601900 | Sep 2008 → Jun 2014 | invasive breast carcinoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 3 | NCT00963729 | Sep 2008 → Mar 2010 | breast cancer | Imperial College London | Completed | No outcome recorded |
| Phase 3 | NCT02338310 | Sep 2008 → Apr 2024 overdue | breast cancer | Institute of Cancer Research, United Kingdom | Active not recruiting | No outcome recorded |
| Phase 3 | NCT00673335 | May 2008 → Jun 2019 | BRCA1-related cancer predisposition, BRCA2-related cancer predisposition, breast cancer, hereditary breast ovarian cancer syndrome | UNICANCER | Completed | No outcome recorded |
| Phase 3 | NCT01577017 | May 2008 → May 2009 | polycystic ovary syndrome | Nik Hazlina | Completed | No outcome recorded |
| Phase 3 | NCT00902954 | Mar 2008 → Jun 2010 | breast cancer | Fudan University | Unknown | No outcome recorded |
| Phase 3 | NCT00545077 | Nov 2007 → Dec 2013 | breast cancer | Spanish Breast Cancer Research Group | Completed | No outcome recorded |
| Phase 3 | NCT00553410 | Aug 2007 → Apr 2018 | breast cancer | ETOP IBCSG Partners Foundation | Completed | No outcome recorded |
| Phase 3 | NCT00541086 | Mar 2007 → Jul 2020 | breast cancer | Gruppo Italiano Mammella (GIM) | Unknown | No outcome recorded |
| Phase 3 | NCT00433589 | Feb 2007 → Mar 2020 | breast cancer | European Organisation for Research and Treatment of Cancer - EORTC | Completed | No outcome recorded |
| Phase 3 | NCT00382070 | Aug 2006 → Aug 2016 | breast cancer | NSABP Foundation Inc | Unknown | No outcome recorded |
| Phase 3 | NCT00403182 | May 2006 → ? | female breast carcinoma | Technical University of Munich | Withdrawn | No outcome recorded |
| Phase 3 | NCT00332852 | Mar 2006 → Jul 2010 | breast cancer | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00330317 | Feb 2006 → Mar 2010 | female breast carcinoma | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00265759 | Jan 2006 → Aug 2012 | breast cancer | Alliance for Clinical Trials in Oncology | Completed | No outcome recorded |
| Phase 3 | NCT00248170 | Dec 2005 → Sep 2014 | breast cancer | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00267553 | Nov 2005 → Jun 2006 | breast neoplasm | Intarcia Therapeutics | Terminated | No outcome recorded |
| Phase 3 | NCT00329940 | Nov 2005 → Jan 2008 | breast cancer | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT01064635 | Aug 2005 → Aug 2015 overdue | breast cancer | IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy | Active not recruiting | No outcome recorded |
| Phase 3 | NCT00138710 | Aug 2005 → Jan 2010 | hypogonadotropic hypogonadism, obesity disorder | Rijnstate Hospital | Completed | No outcome recorded |
| Phase 3 | NCT00146146 | May 2005 → May 2006 | — | Unita Complessa di Ostetricia e Ginecologia | Completed | No outcome recorded |
| Phase 3 | NCT00171704 | Apr 2005 → Mar 2011 | hormone receptor-positive breast cancer | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00097344 | Dec 2004 → Aug 2006 | breast neoplasm | Intarcia Therapeutics | Terminated | No outcome recorded |
| Phase 3 | NCT00610077 | Dec 2004 → Jul 2006 | infertility disorder | Sun Pharmaceutical Industries, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00754845 | Nov 2004 → Dec 2015 | breast cancer | Canadian Cancer Trials Group | Completed | No outcome recorded |
| Phase 3 | NCT00171314 | Mar 2004 → Nov 2010 | breast cancer | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00412022 | Mar 2004 → Nov 2024 | breast cancer | National Cancer Institute, Naples | Unknown | No outcome recorded |
| Phase 3 | NCT00171340 | May 2003 → Feb 2010 | breast cancer, disease of bone structure | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00003140 | Aug 1998 → Aug 2003 | breast cancer | NCIC Clinical Trials Group | Completed | No outcome recorded |
| Phase 3 | NCT00004205 | Mar 1998 → Dec 2008 | breast cancer | ETOP IBCSG Partners Foundation | Completed | No outcome recorded |
| Phase 3 | NCT00001521 | Jun 1995 → Apr 2024 | congenital adrenal hyperplasia | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Completed | No outcome recorded |
| Phase 447 trials | ||||||
| Phase 4 | NCT06985186 | Jun 2025 → Jun 2026 overdue | adenomyosis | University of Palermo | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07160855 | May → Nov 2025 overdue | — | Nishtar Medical University | Recruiting | No outcome recorded |
| Phase 4 | NCT06143631 | Jul 2024 → Sep 2027 expected | uterine corpus leiomyoma | University of California, San Francisco | Recruiting | No outcome recorded |
| Phase 4 | NCT06354439 | Mar 2024 → Dec 2026 expected | tubal pregnancy | Hospital de Clinicas de Porto Alegre | Recruiting | No outcome recorded |
| Phase 4 | NCT05168865 | Aug 2023 → Feb 2024 | polycystic ovary syndrome, pregnancy disorder with abortive outcome | Dubai Fertility Center | Withdrawn | No outcome recorded |
| Phase 4 | NCT04321551 | Jul 2023 → Jun 2028 | — | University of California, San Diego | Withdrawn | No outcome recorded |
| Phase 4 | NCT05341817 | Nov 2022 → Aug 2025 overdue | — | KK Women's and Children's Hospital | Recruiting | No outcome recorded |
| Phase 4 | NCT05362760 | Apr 2022 → Apr 2029 expected | hormone receptor-positive breast cancer | University of Ulm | Recruiting | No outcome recorded |
| Phase 4 | NCT05183828 | Jan 2022 → May 2026 | breast adenocarcinoma, female breast carcinoma, invasive breast carcinoma | University of Washington | Terminated | No outcome recorded |
| Phase 4 | NCT04137640 | Jul 2021 → Nov 2025 | breast cancer | Shengjing Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT05198141 | Dec 2020 → Nov 2021 | ectopic pregnancy | Zagazig University | Completed | No outcome recorded |
| Phase 4 | NCT04002635 | Dec 2020 → Apr 2021 | anovulation, female infertility, polycystic ovary syndrome | CRG UZ Brussel | Withdrawn | No outcome recorded |
| Phase 4 | NCT04590482 | Nov 2020 → Mar 2021 | pregnancy disorder with abortive outcome | Shereen Rady Abou El-fetouh | Unknown | No outcome recorded |
| Phase 4 | NCT05206448 | Oct 2020 → Apr 2024 overdue | infertility disorder, polycystic ovary syndrome | Rachel Mejia | Active not recruiting | No outcome recorded |
| Phase 4 | NCT04215835 | Jan → Apr 2020 | pregnancy disorder with abortive outcome | Cairo University | Unknown | No outcome recorded |
| Phase 4 | NCT04217265 | Jan → Apr 2020 | pregnancy disorder with abortive outcome | Cairo University | Unknown | No outcome recorded |
| Phase 4 | NCT04159649 | Dec 2019 → Dec 2020 | — | Mansoura University | Unknown | No outcome recorded |
| Phase 4 | NCT03948568 | Sep 2019 → Jun 2021 | female breast carcinoma | Ottawa Hospital Research Institute | Completed | No outcome recorded |
| Phase 4 | NCT03901170 | Apr 2019 → Jun 2020 | — | National Taiwan University Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT04834791 | Mar → Oct 2019 | female infertility | Tanta University | Completed | No outcome recorded |
| Phase 4 | NCT04289805 | Feb 2019 → Jan 2025 | female breast carcinoma | Erasme University Hospital | Terminated | No outcome recorded |
| Phase 4 | NCT03238703 | Sep 2018 → Mar 2023 | Her2-receptor negative breast cancer, breast carcinoma in situ, female breast carcinoma, invasive breast carcinoma | Fred Hutchinson Cancer Center | Withdrawn | No outcome recorded |
| Phase 4 | NCT03111615 | May 2018 → May 2019 | female breast carcinoma | Centro Hospitalar Lisboa Ocidental | Unknown | No outcome recorded |
| Phase 4 | NCT03355157 | Mar 2018 → Aug 2024 | breast cancer | GBG Forschungs GmbH | Completed | No outcome recorded |
| Phase 4 | NCT02741154 | Aug 2016 → Aug 2017 | infertility disorder | Minia University | Completed | No outcome recorded |
| Phase 4 | NCT02802865 | Aug 2016 → May 2018 | infertility disorder, polycystic ovary syndrome | Rachel Mejia | Completed | No outcome recorded |
| Phase 4 | NCT02703649 | Mar 2016 → Jul 2020 | anovulation | Mount Sinai Hospital, Canada | Completed | No outcome recorded |
| Phase 4 | NCT02470741 | Jul 2015 → Dec 2017 | leiomyoma | University of California, San Francisco | Completed | No outcome recorded |
| Phase 4 | NCT02288143 | Jan → Mar 2015 | infertility disorder | University of Sao Paulo | Completed | No outcome recorded |
| Phase 4 | NCT01948804 | Jan → Mar 2014 | — | Pınar Özcan Cenksoy | Unknown | No outcome recorded |
| Phase 4 | NCT02097680 | Dec 2013 → Jun 2015 | obesity disorder | University Hospital, Ghent | Completed | No outcome recorded |
| Phase 4 | NCT02661932 | Nov 2012 → Mar 2018 | breast neoplasm, infertility disorder | Erasme University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT02670304 | Jan 2012 → Jul 2013 | ovarian hyperstimulation syndrome | First Affiliated Hospital, Sun Yat-Sen University | Completed | No outcome recorded |
| Phase 4 | NCT01553903 | Dec 2011 → May 2013 | breast cancer | Institut Claudius Regaud | Completed | No outcome recorded |
| Phase 4 | NCT01127295 | Jun 2010 → Dec 2017 | hormone receptor-positive breast cancer | Institut Claudius Regaud | Completed | No outcome recorded |
| Phase 4 | NCT01046578 | Jan 2010 → Feb 2012 | infertility disorder | University of Saskatchewan | Completed | No outcome recorded |
| Phase 4 | NCT01072318 | Jan 2010 → Jan 2014 | breast cancer | Korean Breast Cancer Study Group | Unknown | No outcome recorded |
| Phase 4 | NCT01908556 | Feb 2009 → Dec 2015 | — | Institut fuer Frauengesundheit | Unknown | No outcome recorded |
| Phase 4 | NCT00804960 | Sep 2008 → Dec 2009 | infertility disorder | Center for Human Reproduction | Withdrawn | No outcome recorded |
| Phase 4 | NCT00688909 | Mar 2008 → Jun 2009 | breast cancer | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 4 | NCT01315912 | Jan 2008 → Dec 2010 | female infertility | Bushehr University of Medical Science | Completed | No outcome recorded |
| Phase 4 | NCT01999569 | Apr 2007 → May 2008 | anovulation, ovarian cyst | Wake Forest University Health Sciences | Completed | No outcome recorded |
| Phase 4 | NCT00237133 | Mar 2003 → Jan 2009 | female breast carcinoma | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 4 | NCT00171847 | Mar 2003 → Oct 2008 | breast cancer | Novartis Pharmaceuticals | Terminated | No outcome recorded |
| Phase 4 | NCT00237224 | Feb 2003 → Feb 2007 | breast cancer | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 4 | NCT00241046 | Apr 2002 → Mar 2005 | breast cancer | Novartis Pharmaceuticals | Terminated | No outcome recorded |
| Phase 4 | NCT00014638 | Jan 2001 → Mar 2002 | breast cancer | Novartis | Completed | No outcome recorded |
| Phase not applicable36 trials | ||||||
| — | NCT07425990 | Feb 2026 → Feb 2027 expected | female infertility | University of Novi Sad | Not yet recruiting | No outcome recorded |
| — | NCT07636317 | Jun 2025 → Mar 2026 | pregnancy disorder with abortive outcome | Sohag University | Completed | No outcome recorded |
| — | NCT06810492 | Apr → Dec 2025 overdue | female breast carcinoma | Hongmei Zheng, PhD | Not yet recruiting | No outcome recorded |
| — | NCT06605690 | Oct 2024 → Aug 2025 overdue | breast cancer | Liu Shu | Not yet recruiting | No outcome recorded |
| — | NCT06235931 | Feb 2024 → Dec 2025 overdue | breast neoplasm | Second Affiliated Hospital of Soochow University | Recruiting | No outcome recorded |
| — | NCT06006091 | Aug 2023 → Aug 2026 overdue | female infertility | International Peace Maternity and Child Health Hospital | Recruiting | No outcome recorded |
| — | NCT05940233 | Jun 2023 → May 2025 overdue | — | Queen Savang Vadhana Memorial Hospital, Thailand | Recruiting | No outcome recorded |
| — | NCT05487092 | Dec 2022 → Dec 2026 expected | ovarian endometriosis | The University of Hong Kong | Recruiting | No outcome recorded |
| — | NCT04169451 | Sep 2022 → Dec 2025 | infertility disorder | Peking University Third Hospital | Unknown | No outcome recorded |
| — | NCT06041204 | May 2021 → May 2026 overdue | female infertility, hypothyroidism, polycystic ovary syndrome | Muhamed Ahmed Abdelmoaty Muhamed Alhagrasy | Recruiting | No outcome recorded |
| — | NCT04193930 | Jan 2021 | — | Assiut University | Withdrawn | No outcome recorded |
| — | NCT05075863 | Jan → Jun 2021 | polycystic ovary syndrome | Nishtar Medical University | Completed | No outcome recorded |
| — | NCT04619914 | Mar → Jul 2019 | — | Laylay Mohammed Khalleefah Alhibshi | Completed | No outcome recorded |
| — | NCT03540979 | Jun 2018 → Dec 2019 | — | Meir Medical Center | Unknown | No outcome recorded |
| — | NCT03455426 | Mar 2018 → Jun 2019 | infertility disorder | Peking University Third Hospital | Completed | No outcome recorded |
| — | NCT02775877 | May 2016 → Jun 2019 | female infertility | Navy General Hospital, Beijing | Unknown | No outcome recorded |
| — | NCT03181919 | Jan 2016 → Jan 2017 | polycystic ovary syndrome | Benha University | Completed | No outcome recorded |
| — | NCT02647424 | Dec 2015 → Dec 2017 | infertility disorder, polycystic ovary syndrome | The University of Hong Kong | Unknown | No outcome recorded |
| — | NCT02583828 | Jun 2015 → Dec 2020 | breast neoplasm, metastatic malignant neoplasm | Capital Medical University | Completed | No outcome recorded |
| — | NCT02377479 | Mar 2015 → Mar 2017 | infertility disorder | University Hospitals Cleveland Medical Center | Withdrawn | No outcome recorded |
| — | NCT01793038 | Mar 2013 → Jun 2014 | infertility disorder, polycystic ovary syndrome | Mansoura Integrated Fertility Center | Unknown | No outcome recorded |
| — | NCT01720602 | Nov 2012 → Mar 2015 | male breast carcinoma | University of Washington | Completed | No outcome recorded |
| — | NCT01669343 | Oct 2012 → Dec 2016 | breast neoplasm | Samuel Lunenfeld Research Institute, Mount Sinai Hospital | Completed | No outcome recorded |
| — | NCT01780610 | Jan 2012 → Jan 2015 | infertility disorder | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Unknown | No outcome recorded |
| — | NCT01475318 | Oct 2011 → Jun 2012 | — | The University of Hong Kong | Unknown | No outcome recorded |
| — | NCT01457703 | Jun 2010 → Jul 2013 | obesity disorder | University of Colorado, Denver | Completed | No outcome recorded |
| — | NCT00997373 | Oct 2009 → Sep 2013 | endometrial carcinoma | University of California, Davis | Completed | No outcome recorded |
| — | NCT01116167 | Oct 2009 → Dec 2013 | polycystic ovary syndrome | Heilongjiang University of Chinese Medicine | Unknown | No outcome recorded |
| — | NCT01431352 | Sep 2009 → Aug 2014 | polycystic ovary syndrome | Heilongjiang University of Chinese Medicine | Unknown | No outcome recorded |
| — | NCT01679574 | Jan 2009 → Jan 2012 | polycystic ovary syndrome | Assiut University | Completed | No outcome recorded |
| — | NCT00894608 | Jan 2008 → Dec 2009 | polycystic ovary syndrome | Yunyang Medical College | Unknown | No outcome recorded |
| — | NCT00565240 | Nov 2007 → Sep 2009 | — | University of Saskatchewan | Completed | No outcome recorded |
| — | NCT01334762 | May 2007 → Jun 2010 | endometriosis | Mansoura University | Completed | No outcome recorded |
| — | NCT00956267 | Aug 2006 → Mar 2009 | polycystic ovary syndrome | Mansoura University | Completed | No outcome recorded |
| — | NCT00911313 | Jun 2006 → Jan 2009 | polycystic ovary syndrome | Mansoura University | Completed | No outcome recorded |
| — | NCT00114270 | May 2004 → Jun 2007 | breast cancer, osteoporosis | University of Virginia | Completed | No outcome recorded |
Also used as a comparator or background therapy in 300 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 06 trials | ||||||
| Phase 0 | NCT05464810 Background | Sep 2022 → Apr 2027 expected | female breast carcinoma, hormone receptor-positive breast cancer, invasive breast carcinoma | Emory University | Recruiting | No outcome recorded |
| Phase 0 | NCT04088032 Background | Oct 2019 → Dec 2020 | female breast carcinoma, hormone receptor-positive breast cancer | Alison Stopeck | Withdrawn | No outcome recorded |
| Phase 0 | NCT03962647 Background | Jul 2019 → Mar 2024 | estrogen-receptor positive breast cancer | Vanderbilt-Ingram Cancer Center | Completed | No outcome recorded |
| Phase 0 | NCT02538484 Comparator | Apr 2016 → Mar 2020 | breast cancer | The University of Texas Health Science Center at San Antonio | Completed | No outcome recorded |
| Phase 0 | NCT02341703 Comparator | Feb → Jul 2015 | infertility disorder, polycystic ovary syndrome | Cairo University | Completed | No outcome recorded |
| Phase 0 | NCT01909141 Comparator | Aug 2013 → Feb 2014 | infertility disorder, polycystic ovary syndrome | Cairo University | Completed | No outcome recorded |
| Phase 118 trials | ||||||
| Phase 1 | NCT07029399 Background | Mar 2025 → Jul 2027 expected | hormone receptor-positive breast cancer, triple-negative breast carcinoma | NiKang Therapeutics, Inc. | Recruiting | No outcome recorded |
| Phase 1 | NCT06218303 Background | Feb 2024 → Aug 2026 overdue | ductal breast carcinoma in situ | Finn, Olivera, PhD | Recruiting | No outcome recorded |
| Phase 1 | NCT06367712 Comparator | Nov 2022 → Nov 2023 | polycystic ovary syndrome | Egymedicalpedia | Completed | No outcome recorded |
| Phase 1 | NCT05307705 Background | May 2022 → Dec 2026 expected | breast cancer | Eli Lilly and Company | Recruiting | No outcome recorded |
| Phase 1 | NCT06570031 Background | Nov 2021 → Apr 2026 | hormone receptor-positive breast cancer | Ono Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT04895761 Background | Sep 2021 → Jun 2023 overdue | breast cancer | Providence Health & Services | Active not recruiting | No outcome recorded |
| Phase 1 | NCT04872608 Background | Sep 2021 → Apr 2023 | breast carcinoma, metastatic neoplasm | Memorial Sloan Kettering Cancer Center | Withdrawn | No outcome recorded |
| Phase 1 | NCT04856371 Background | Apr 2021 → Mar 2022 | breast cancer | Haihe Biopharma Co., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT03846583 Background | Jun → Sep 2020 | breast cancer | Dana-Farber Cancer Institute | Withdrawn | No outcome recorded |
| Phase 1 | NCT03900884 Background | Sep 2019 → Jun 2025 overdue | breast neoplasm | Peter MacCallum Cancer Centre, Australia | Active not recruiting | No outcome recorded |
| Phase 1 | NCT02499146 Background | Sep 2015 → Jul 2018 | female breast carcinoma | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT01655225 Background | Jul 2012 → Apr 2019 | breast cancer, cancer of unknown primary site, malignant mesothelioma, metastatic malignant neoplasm +2 | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT01296555 Background | Mar 2011 → Jun 2021 | non-Hodgkin lymphoma | Genentech, Inc. | Terminated | No outcome recorded |
| Phase 1 | NCT01199367 Background | Dec 2010 → Dec 2012 | breast cancer | Kyowa Kirin, Inc. | Terminated | No outcome recorded |
| Phase 1 | NCT00960960 Background | Aug 2009 → Dec 2015 | breast cancer | Genentech, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00790816 Background | Oct 2008 → Aug 2016 | breast neoplasm | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT00508586 Background | Nov 2007 → Mar 2012 | breast cancer | PTC Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT00516542 Background | Jun 2007 → Jul 2009 | breast cancer | OHSU Knight Cancer Institute | Terminated | No outcome recorded |
| Phase 1/211 trials | ||||||
| Phase 1/2 | NCT07596212 Background | Jul 2026 → Jul 2028 expected | hormone receptor-positive breast cancer, hypoactive sexual desire disorder | University of Illinois at Chicago | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07708194 Background | Jun 2025 → Feb 2027 expected | HER2 positive breast carcinoma, hormone receptor-positive breast cancer | Tianjin Medical University Cancer Institute and Hospital | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06974929 Background | May 2025 → Dec 2026 expected | breast cancer | Jiangsu HengRui Medicine Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05768139 Background | Apr 2023 → Jul 2030 expected | breast cancer | Eli Lilly and Company | Recruiting | No outcome recorded |
| Phase 1/2 | NCT03774472 Background | Aug 2018 → Apr 2024 | female breast carcinoma | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 1/2 | NCT04539496 Background | May 2018 → Jul 2023 overdue | breast cancer, metastatic neoplasm | Sihuan Pharmaceutical Holdings Group Ltd. | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT01872260 Background | Oct 2013 → Feb 2027 expected | breast cancer | Novartis Pharmaceuticals | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT01791985 Background | Jul 2012 → Nov 2016 | breast cancer | Imperial College London | Completed | No outcome recorded |
| Phase 1/2 | NCT01082068 Background | Jun 2010 → Apr 2013 | breast cancer | Sanofi | Completed | No outcome recorded |
| Phase 1/2 | NCT00634634 Background | Aug 2008 → Apr 2019 | breast cancer | Rutgers, The State University of New Jersey | Completed | No outcome recorded |
| Phase 1/2 | NCT00823004 Comparator | Jun 2008 → Feb 2009 | ovarian hyperstimulation syndrome | Yazd Research & Clinical Center for Infertility | Completed | No outcome recorded |
| Phase 2111 trials | ||||||
| Phase 2 | NCT07679269 Background | Jan 2027 → Jun 2031 expected | PIK3CA-related overgrowth spectrum, breast neoplasm | Novartis Pharmaceuticals | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07676331 Comparator | Aug 2026 → Mar 2028 expected | female breast carcinoma, hormone receptor-positive breast cancer | Universitaire Ziekenhuizen KU Leuven | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07691333 Background | Jun 2026 → Jan 2028 expected | hormone receptor-positive breast cancer | Fujian Cancer Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07610720 Background | Jun 2026 → Nov 2028 expected | HER2 positive breast carcinoma | Sun Yat-sen University | Recruiting | No outcome recorded |
| Phase 2 | NCT07624903 Comparator | Jun 2026 → Jun 2027 expected | ectopic pregnancy | Kafrelsheikh University | Not yet recruiting | No outcome recorded |
| Show all 111 trials opens the full record — a long page | ||||||
| Phase 2/311 trials | ||||||
| Phase 2/3 | NCT05860465 Background | Sep 2023 → Dec 2026 expected | breast cancer | Shanghai Pharmaceuticals Holding Co., Ltd | Recruiting | No outcome recorded |
| Phase 2/3 | NCT05744687 Background | Apr 2023 → May 2026 overdue | breast cancer | Shanghai Pharmaceuticals Holding Co., Ltd | Recruiting | No outcome recorded |
| Phase 2/3 | NCT05523609 Background | Nov 2022 → Sep 2024 | breast cancer | Tanta University | Unknown | No outcome recorded |
| Phase 2/3 | NCT02946684 Comparator | Feb 2017 → Oct 2018 | infertility disorder | Sven O. Skouby | Completed | No outcome recorded |
| Phase 2/3 | NCT02939898 Comparator | Aug 2016 → Jan 2018 | infertility disorder | Sven O. Skouby | Completed | No outcome recorded |
| Phase 2/3 | NCT02401425 Comparator | Mar → Sep 2015 | — | Ain Shams University | Completed | No outcome recorded |
| Phase 2/3 | NCT02101788 Comparator | Apr 2014 → Apr 2019 | borderline ovarian serous tumor, micropapillary serous carcinoma, ovarian serous adenocarcinoma, primary peritoneal serous adenocarcinoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2/3 | NCT01797718 Comparator | Oct 2013 → Mar 2017 | constitutional delay of growth and puberty | Helsinki University Central Hospital | Completed | No outcome recorded |
| Phase 2/3 | NCT03440359 Background | Jul 2012 → Nov 2016 | polycystic ovary syndrome | Eastern Virginia Medical School | Completed | No outcome recorded |
| Phase 2/3 | NCT00684216 Comparator | Apr 2008 → May 2012 | breast cancer | The Netherlands Cancer Institute | Terminated | No outcome recorded |
| Phase 2/3 | NCT01218581 Comparator | Dec 2005 → Jan 2010 | — | Mansoura University | Completed | No outcome recorded |
| Phase 384 trials | ||||||
| Phase 3 | NCT07492641 Background | May 2026 → Apr 2029 expected | hormone receptor-positive breast cancer | BeOne Medicines | Recruiting | No outcome recorded |
| Phase 3 | NCT06405178 Background | Mar 2026 | polycystic ovary syndrome | Beni-Suef University | Completed | No outcome recorded |
| Phase 3 | NCT07349069 Comparator | Mar 2026 → Dec 2030 expected | breast cancer | Shandong Suncadia Medicine Co., Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT07400523 Background | Feb 2026 → Feb 2030 expected | breast cancer | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Recruiting | No outcome recorded |
| Phase 3 | NCT06585969 Comparator | Jan 2026 | basal-like breast carcinoma, estrogen-receptor positive breast cancer, luminal B breast carcinoma | Danish Breast Cancer Cooperative Group | Withdrawn | No outcome recorded |
| Phase 3 | NCT07296614 Background | Dec 2025 → Jul 2028 expected | female infertility, ovarian dysfunction | Peking Union Medical College Hospital | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07174336 Background | Dec 2025 → May 2029 expected | breast cancer, metastatic neoplasm | Eli Lilly and Company | Recruiting | No outcome recorded |
| Phase 3 | NCT07085767 Comparator | Nov 2025 → Dec 2028 expected | Her2-receptor negative breast cancer, estrogen-receptor positive breast cancer | Olema Pharmaceuticals, Inc. | Recruiting | No outcome recorded |
| Phase 3 | NCT07024173 Comparator | Jul 2025 → Dec 2026 expected | female breast carcinoma | Shandong Suncadia Medicine Co., Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT07061717 Comparator | Jul 2025 → Jul 2029 expected | hormone receptor-positive breast cancer | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07019363 Comparator | Jun 2025 → May 2029 expected | breast cancer | Fudan University | Recruiting | No outcome recorded |
| Phase 3 | NCT06790693 Background | Apr 2025 → May 2032 expected | breast cancer | Hoffmann-La Roche | Recruiting | No outcome recorded |
| Phase 3 | NCT06671912 Comparator | Feb 2025 → Nov 2030 | Her2-receptor negative breast cancer, ductal breast carcinoma in situ, estrogen-receptor positive breast cancer, lobular breast carcinoma in situ | Alliance for Clinical Trials in Oncology | Suspended | No outcome recorded |
| Phase 3 | NCT07190443 Comparator | Feb 2025 → Feb 2034 expected | breast cancer | Japanese Foundation for Cancer Research | Recruiting | No outcome recorded |
| Phase 3 | NCT06760637 Background | Jan 2025 → Jan 2029 expected | breast cancer | Pfizer | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06380751 Comparator | Aug 2024 → Mar 2029 expected | female breast carcinoma | AstraZeneca | Recruiting | No outcome recorded |
| Phase 3 | NCT06044623 Background | Apr 2024 → Oct 2028 expected | breast cancer | Region Örebro County | Recruiting | No outcome recorded |
| Phase 3 | NCT06072781 Comparator | Mar 2024 → Oct 2028 expected | ovarian serous tumor | Verastem, Inc. | Recruiting | No outcome recorded |
| Phase 3 | NCT05827081 Background | Feb 2024 → Sep 2029 expected | female breast carcinoma | Novartis Pharmaceuticals | Recruiting | No outcome recorded |
| Phase 3 | NCT06447623 Background | Feb 2024 → Feb 2027 expected | hormone receptor-positive breast cancer | Fudan University | Recruiting | No outcome recorded |
| Phase 3 | NCT05512364 Comparator | Dec 2023 → Nov 2032 expected | Her2-receptor negative breast cancer, estrogen-receptor positive breast cancer | European Organisation for Research and Treatment of Cancer - EORTC | Recruiting | No outcome recorded |
| Phase 3 | NCT02686151 Comparator | Dec 2023 → Mar 2024 | ovarian hyperstimulation syndrome | The Affiliated Hospital of Inner Mongolia Medical University | Unknown | No outcome recorded |
| Phase 3 | NCT06016738 Comparator | Nov 2023 → Jun 2026 overdue | Her2-receptor negative breast cancer, estrogen-receptor positive breast cancer | Olema Pharmaceuticals, Inc. | Recruiting | No outcome recorded |
| Phase 3 | NCT05952557 Comparator | Oct 2023 → Mar 2030 expected | breast carcinoma | AstraZeneca | Recruiting | No outcome recorded |
| Phase 3 | NCT05894239 Background | Sep 2023 → Dec 2026 expected | breast cancer | Hoffmann-La Roche | Recruiting | No outcome recorded |
| Phase 3 | NCT05909397 Comparator | Aug 2023 → Dec 2026 expected | breast cancer | Pfizer | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05891093 Background | Jun 2023 → May 2028 expected | breast cancer | Fudan University | Recruiting | No outcome recorded |
| Phase 3 | NCT05861830 Background | May 2023 → Dec 2025 | female breast carcinoma | Peking Union Medical College Hospital | Unknown | No outcome recorded |
| Phase 3 | NCT05712941 Background | Apr 2023 → Mar 2024 | endometrial carcinoma | EQRx International, Inc. | Withdrawn | No outcome recorded |
| Phase 3 | NCT05774951 Comparator | Mar 2023 → Apr 2027 expected | breast carcinoma | AstraZeneca | Recruiting | No outcome recorded |
| Phase 3 | NCT05780567 Background | Mar 2023 → Dec 2026 expected | breast cancer | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05645536 Background | Dec 2022 → Jun 2028 expected | breast cancer | Tolmar Inc. | Enrolling by invitation | No outcome recorded |
| Phase 3 | NCT05514054 Comparator | Oct 2022 → Oct 2027 expected | breast neoplasm | Eli Lilly and Company | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05207709 Background | Mar 2022 → Mar 2026 | breast cancer | SOLTI Breast Cancer Research Group | Terminated | No outcome recorded |
| Phase 3 | NCT05257395 Background | Mar 2022 → Dec 2025 overdue | female breast carcinoma | Xuanzhu Biopharmaceutical Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05439499 Comparator | Mar 2022 → Sep 2024 | female breast carcinoma | Ahon Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
| Phase 3 | NCT05851014 Background | Jan 2022 → Jan 2026 overdue | breast cancer | Genor Biopharma Co., Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT04961996 Comparator | Aug 2021 → Aug 2025 overdue | breast cancer | Hoffmann-La Roche | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04906395 Background | Jul 2021 → Apr 2026 overdue | female breast carcinoma | Tolmar Inc. | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04964934 Comparator | Jun 2021 → Jun 2025 overdue | estrogen-receptor positive breast cancer | AstraZeneca | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04852887 Comparator | Jun 2021 → Apr 2031 expected | female breast carcinoma | NRG Oncology | Recruiting | No outcome recorded |
| Phase 3 | NCT04134598 Comparator | Feb 2021 → Mar 2030 expected | breast cancer | Careggi University Hospital | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04584853 Background | Dec 2020 → Oct 2030 expected | female breast carcinoma | Institute of Cancer Research, United Kingdom | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04478266 Comparator | Oct 2020 → Jun 2022 | breast cancer | Sanofi | Terminated | No outcome recorded |
| Phase 3 | NCT04546009 Comparator | Oct 2020 → Jan 2026 overdue | estrogen-receptor positive breast cancer | Hoffmann-La Roche | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04356105 Comparator | Jun 2020 → Sep 2021 | female infertility | Cairo University | Completed | No outcome recorded |
| Phase 3 | NCT04047758 Comparator | Sep 2019 → Sep 2021 | breast cancer | Shengjing Hospital | Unknown | No outcome recorded |
| Phase 3 | NCT03820830 Background | Aug 2019 → Jul 2026 overdue | breast cancer | ETOP IBCSG Partners Foundation | Active not recruiting | No outcome recorded |
| Phase 3 | NCT03966898 Background | Jul 2019 → Dec 2022 | female breast carcinoma | Jiangsu HengRui Medicine Co., Ltd. | Unknown | No outcome recorded |
| Phase 3 | NCT03969121 Comparator | Jul 2019 → Dec 2021 | female breast carcinoma, hormone receptor-positive breast cancer | Kyoto Breast Cancer Research Network | Completed | No outcome recorded |
| Phase 3 | NCT03778931 Comparator | May 2019 → Aug 2021 | breast cancer | Stemline Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT03625531 Comparator | Aug 2018 → Jan 2025 | polycystic ovary syndrome | Hongxia Ma | Completed | No outcome recorded |
| Phase 3 | NCT03081234 Background | Mar 2018 → Nov 2025 | breast cancer | Novartis Pharmaceuticals | Withdrawn | No outcome recorded |
| Phase 3 | NCT03425838 Comparator | Nov 2017 → Mar 2023 overdue | breast cancer | Dutch Breast Cancer Research Group | Active not recruiting | No outcome recorded |
| Phase 3 | NCT02767661 Background | Jul 2017 → Aug 2023 | breast cancer | Sun Yat-sen University | Completed | No outcome recorded |
| Phase 3 | NCT02947685 Background | Jun 2017 → Oct 2024 overdue | HER2 positive breast carcinoma, estrogen-receptor positive breast cancer | Alliance Foundation Trials, LLC. | Active not recruiting | No outcome recorded |
| Phase 3 | NCT03050398 Background | Jun 2017 → Mar 2019 | breast cancer | Novartis Pharmaceuticals | Terminated | No outcome recorded |
| Phase 3 | NCT03009838 Comparator | Jan 2017 → Dec 2022 | infertility disorder | Assiut University | Unknown | No outcome recorded |
| Phase 3 | NCT02763566 Background | Dec 2016 → Mar 2019 overdue | breast cancer | Eli Lilly and Company | Active not recruiting | No outcome recorded |
| Phase 3 | NCT02297438 Comparator | Mar 2015 → Aug 2020 | breast neoplasm | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT02278120 Background | Nov 2014 → Aug 2017 | breast cancer | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT02246621 Background | Nov 2014 → Jan 2017 overdue | breast cancer | Eli Lilly and Company | Active not recruiting | No outcome recorded |
| Phase 3 | NCT02305693 Comparator | Nov 2014 → May 2017 | infertility disorder | Cairo University | Unknown | No outcome recorded |
| Phase 3 | NCT02511639 Background | Jul 2014 → Feb 2020 | breast cancer | Veneto Institute of Oncology IRCCS | Completed | No outcome recorded |
| Phase 3 | NCT02739516 Background | Jun 2014 → Aug 2015 | infertility disorder | Benha University | Completed | No outcome recorded |
| Phase 3 | NCT01958021 Background | Dec 2013 → Jan 2016 | breast cancer | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT01674140 Background | Sep 2013 → Dec 2022 overdue | breast cancer | SWOG Cancer Research Network | Active not recruiting | No outcome recorded |
| Phase 3 | NCT02304107 Comparator | May 2013 → Jan 2015 | infertility disorder | Cairo University | Completed | No outcome recorded |
| Phase 3 | NCT01740427 Comparator | Feb 2013 → Feb 2016 | breast cancer | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT01619111 Comparator | Feb 2012 → Jan 2022 | HER2 positive breast carcinoma, Her2-receptor negative breast cancer | University of Ulm | Completed | No outcome recorded |
| Phase 3 | NCT02995772 Comparator | Nov 2011 → Nov 2018 | breast cancer | Dharmais National Cancer Center Hospital | Completed | No outcome recorded |
| Phase 3 | NCT01160211 Background | May 2011 → Mar 2016 | breast neoplasm | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT01272037 Background | Feb 2011 → Feb 2023 overdue | ductal breast carcinoma in situ, invasive breast carcinoma, synchronous bilateral breast carcinoma | National Cancer Institute (NCI) | Active not recruiting | No outcome recorded |
| Phase 3 | NCT01248416 Comparator | Nov 2010 → Sep 2016 | isolated short stature | Nemours Children's Clinic | Completed | No outcome recorded |
| Phase 3 | NCT01044862 Comparator | Jun 2010 → Oct 2013 | infertility disorder, pregnancy disorder | Yale University | Completed | No outcome recorded |
| Phase 3 | NCT00719186 Comparator | Feb 2009 → May 2013 | polycystic ovary syndrome, pregnancy disorder | Yale University | Completed | No outcome recorded |
| Phase 3 | NCT00688194 Comparator | May 2008 → May 2013 | breast cancer | Gruppo Italiano Mammella (GIM) | Unknown | No outcome recorded |
| Phase 3 | NCT00310180 Background | Apr 2006 → Mar 2018 overdue | breast adenocarcinoma, hormone receptor-positive breast cancer | National Cancer Institute (NCI) | Active not recruiting | No outcome recorded |
| Phase 3 | NCT00332709 Background | Jan 2006 → Aug 2010 | postmenopausal osteoporosis | Novartis | Completed | No outcome recorded |
| Phase 3 | NCT00107263 Background | Jan 2005 → Mar 2007 | breast cancer, osteoporosis | Alliance for Clinical Trials in Oncology | Completed | No outcome recorded |
| Phase 3 | NCT00083993 Background | May 2004 → Oct 2006 | breast cancer, metastatic malignant neoplasm | Wyeth is now a wholly owned subsidiary of Pfizer | Terminated | No outcome recorded |
| Phase 3 | NCT00073528 Background | Dec 2003 → Jun 2008 | breast neoplasm | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00050011 Background | Sep 2002 → Jan 2009 | breast neoplasm, osteoporosis | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00044291 Comparator | Jun 2002 → Jan 2006 | breast neoplasm | Intarcia Therapeutics | Completed | No outcome recorded |
| Phase 417 trials | ||||||
| Phase 4 | NCT06181305 Comparator | Feb → Nov 2024 | — | Rahem Fertility Center | Unknown | No outcome recorded |
| Phase 4 | NCT07589075 Background | Oct 2023 → Jul 2024 | — | Beni-Suef University | Completed | No outcome recorded |
| Phase 4 | NCT05809024 Background | Mar 2023 → Mar 2025 | female breast carcinoma, hormone receptor-positive breast cancer | Yongsheng Wang | Unknown | No outcome recorded |
| Phase 4 | NCT05161195 Background | Jul 2022 → Jun 2030 expected | metastatic malignant neoplasm | Novartis Pharmaceuticals | Active not recruiting | No outcome recorded |
| Phase 4 | NCT05362799 Comparator | Jun 2022 → Dec 2023 | female infertility | Menoufia University | Unknown | No outcome recorded |
| Phase 4 | NCT05205837 Comparator | Nov 2021 → Aug 2023 | hypogonadism, male, hypogonadotropic hypogonadism | Rigshospitalet, Denmark | Terminated | No outcome recorded |
| Phase 4 | NCT04707196 Background | Feb 2021 → Jan 2023 | breast cancer, metastatic malignant neoplasm | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 4 | NCT04364581 Comparator | May 2020 → May 2021 | submucous uterine fibroid | Mansoura University | Unknown | No outcome recorded |
| Phase 4 | NCT04331197 Comparator | May 2020 → May 2021 | female infertility | Cairo University | Unknown | No outcome recorded |
| Phase 4 | NCT04069117 Comparator | Aug 2019 → Feb 2022 | polycystic ovary syndrome | Mansoura University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT03220178 Background | Jul 2017 → Dec 2021 | breast cancer | Palleos Healthcare GmbH | Terminated | No outcome recorded |
| Phase 4 | NCT02679755 Background | Mar 2016 → Jul 2019 | female breast carcinoma | Pfizer | Completed | No outcome recorded |
| Phase 4 | NCT01612871 Background | Jun 2012 → Jan 2016 | female breast carcinoma | Institut Claudius Regaud | Completed | No outcome recorded |
| Phase 4 | NCT02137538 Comparator | Nov 2009 → Jun 2018 | isolated short stature | Stanford University | Completed | No outcome recorded |
| Phase 4 | NCT01035099 Comparator | Nov 2009 → Jul 2019 | breast cancer, infertility disorder | Weill Medical College of Cornell University | Completed | No outcome recorded |
| Phase 4 | NCT00478504 Comparator | May 2007 → Jun 2014 | infertility disorder, polycystic ovary syndrome | University of Nottingham | Completed | No outcome recorded |
| Phase 4 | NCT00375752 Background | Jun 2006 → Dec 2010 | breast neoplasm | Novartis Pharmaceuticals | Terminated | No outcome recorded |
| Phase not applicable41 trials | ||||||
| — | NCT06913075 Comparator | Jun → Jul 2026 overdue | adenomyosis | Indira IVF Hospital Pvt Ltd | Not yet recruiting | No outcome recorded |
| — | NCT07379502 Comparator | Mar → Jun 2026 overdue | polycystic ovary syndrome | CMH Kharian Medical College | Not yet recruiting | No outcome recorded |
| — | NCT07159880 Comparator | Sep 2025 → Jul 2026 overdue | anovulation, female infertility, polycystic ovary syndrome | GABRIEL MONTEIRO PINHEIRO | Recruiting | No outcome recorded |
| — | NCT07065539 Comparator | Jul 2025 → May 2027 expected | adenomyosis | First Affiliated Hospital, Sun Yat-Sen University | Not yet recruiting | No outcome recorded |
| — | NCT07109947 Comparator | Jul → Dec 2025 overdue | pregnancy disorder with abortive outcome | Aswan University | Recruiting | No outcome recorded |
| — | NCT07000344 Background | Jul 2025 → Mar 2026 | ovarian cancer | Peking Union Medical College Hospital | Terminated | No outcome recorded |
| — | NCT06928844 Background | Apr → Aug 2025 overdue | — | The General Authority for Teaching Hospitals and Institutes | Recruiting | No outcome recorded |
| — | NCT07448272 Comparator | Apr 2025 → Apr 2026 overdue | polycystic ovary syndrome | Mst.Sumyara Khatun | Active not recruiting | No outcome recorded |
| — | NCT07255911 Comparator | Feb 2025 → Jan 2026 overdue | polycystic ovary syndrome | Mst.Sumyara Khatun | Recruiting | No outcome recorded |
| — | NCT06793904 Background | Feb 2025 → Jan 2026 overdue | polycystic ovary syndrome | Cairo University | Recruiting | No outcome recorded |
| — | NCT06733727 Comparator | Dec 2024 → Dec 2027 expected | — | The University of Hong Kong | Not yet recruiting | No outcome recorded |
| — | NCT06507332 Comparator | Mar → Sep 2024 | polycystic ovary syndrome | Egymedicalpedia | Unknown | No outcome recorded |
| — | NCT05890287 Background | May 2023 → May 2026 overdue | hormone receptor-positive breast cancer | Tianjin Medical University Cancer Institute and Hospital | Recruiting | No outcome recorded |
| — | NCT07168837 Comparator | Jan 2023 → May 2024 | polycystic ovary syndrome | Al-Azhar University | Completed | No outcome recorded |
| — | NCT06413771 Comparator | Jan 2023 → Jan 2024 | female infertility | Uludag University | Completed | No outcome recorded |
| — | NCT06426979 Comparator | Jan → Jun 2023 | tubal pregnancy | Zagazig University | Completed | No outcome recorded |
| — | NCT06120595 Background | Nov 2022 → Nov 2023 | — | Helse Stavanger HF | Unknown | No outcome recorded |
| — | NCT05198050 Comparator | Apr → Sep 2022 | — | Cairo University | Completed | No outcome recorded |
| — | NCT05874518 Comparator | Dec 2021 → Apr 2022 | ovarian dysfunction | Liuzhou Maternity and Child Healthcare Hospital | Completed | No outcome recorded |
| — | NCT05166668 Comparator | Nov 2021 → Feb 2025 | ovarian hyperstimulation syndrome | Menoufia University | Completed | No outcome recorded |
| — | NCT05106712 Comparator | Nov 2021 → Jul 2023 | female infertility, polycystic ovary syndrome, vitamin D deficiency | Umm Al-Qura University | Unknown | No outcome recorded |
| — | NCT06504082 Comparator | Sep 2021 → Sep 2022 | tubal pregnancy | Yuzuncu Yil University | Completed | No outcome recorded |
| — | NCT05839574 Comparator | Jan 2021 → Dec 2022 | uterine disorder | Jagiellonian University | Completed | No outcome recorded |
| — | NCT05839561 Comparator | Dec 2020 → Dec 2022 | tubal pregnancy | Jagiellonian University | Completed | No outcome recorded |
| — | NCT04308343 Comparator | Mar 2020 → Mar 2022 | ectopic pregnancy | Assiut University | Unknown | No outcome recorded |
| — | NCT05437471 Comparator | Jan 2020 → Dec 2021 | pregnancy loss, recurrent, 4 | Universiti Kebangsaan Malaysia Medical Centre | Completed | No outcome recorded |
| — | NCT03870919 Background | Oct 2019 → Aug 2024 overdue | female breast carcinoma | UNICANCER | Active not recruiting | No outcome recorded |
| — | NCT03400683 Comparator | Jan → Jun 2018 | — | Cairo University | Unknown | No outcome recorded |
| — | NCT02865681 Background | Jul 2016 → Jun 2017 | infertility disorder | New Hope Fertility Center | Completed | No outcome recorded |
| — | NCT02701348 Background | May 2016 → Dec 2020 | breast cancer | NHS Tayside | Completed | No outcome recorded |
| — | NCT02630485 Comparator | Dec 2015 → Mar 2018 | infertility disorder, polycystic ovary syndrome | University of British Columbia | Unknown | No outcome recorded |
| — | NCT02095184 Comparator | May 2015 → Jul 2024 | breast cancer | University of Maryland, Baltimore | Terminated | No outcome recorded |
| — | NCT02128360 Comparator | Mar 2015 → Jun 2016 | infertility disorder | Sheba Medical Center | Unknown | No outcome recorded |
| — | NCT02293668 Comparator | Nov 2014 → Aug 2015 | infertility disorder | Istanbul University | Completed | No outcome recorded |
| — | NCT02450175 Comparator | Jun 2014 → Jun 2016 | neoplasm | Sinai Hospital of Baltimore | Unknown | No outcome recorded |
| — | NCT02158689 Comparator | Jun 2014 → Aug 2015 | — | Ercan Bastu | Completed | No outcome recorded |
| — | NCT02010021 Comparator | Jan 2014 → Dec 2017 | breast cancer | Dartmouth-Hitchcock Medical Center | Completed | No outcome recorded |
| — | NCT02294773 Comparator | Oct 2013 → Sep 2015 | infertility disorder | Midwest Fertility Specialists | Completed | No outcome recorded |
| — | NCT01897441 Background | Jun 2013 → Oct 2023 | female breast carcinoma | Albert Einstein College of Medicine | Terminated | No outcome recorded |
| — | NCT01153672 Background | Nov 2010 → Jul 2012 | male breast carcinoma | University of Washington | Completed | No outcome recorded |
| — | NCT02389088 Comparator | Apr 2006 → Jan 2013 | polycystic ovary syndrome | University of California, San Diego | Completed | No outcome recorded |
| Phase not stated1 trial | ||||||
| — | NCT02142868 Background | — | Her2-receptor negative breast cancer | Pfizer | No longer available | No outcome recorded |
Press releases naming this drug 5 releases
| Date | Issuer | Release |
|---|---|---|
| 2017-12-06 | Pfizer | Updated Data from Phase 3 Trial of IBRANCE® (palbociclib) Plus Letrozole in ER+, HER2- Metastatic Breast Cancer Confirm Improvement in Progression-Free Survival pfizer.com ↗ |
| 2017-06-02 | Novartis Pharmaceuticals | Novartis presents updated data that reinforce the efficacy and safety of Kisqali® (ribociclib) plus letrozole as a first-line option for HR+/HER2- advanced or metastatic breast cancer novartis.com ↗ |
| 2016-12-09 | Novartis Pharmaceuticals | Novartis LEE011 (ribociclib) plus letrozole analyses show superior PFS across broad spectrum of patients in first-line HR+/HER2- advanced breast cancer versus letrozole novartis.com ↗ |
| 2016-10-08 | Novartis Pharmaceuticals | Novartis breakthrough therapy LEE011 plus letrozole demonstrates superior progression-free survival as first-line treatment for HR+/HER2- advanced breast cancer compared to a standard of care novartis.com ↗ |
| 2010-01-21 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Announces Tentative Approval of Generic Femara® Tablets tevapharm.com ↗ |
Evidence & citations 24 cited values
Every value below carries the sentence it was read from. 758 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Létrozole | “POETIC was an open-label, multicentre, parallel-group, randomised, phase 3 trial (done in 130 UK hospitals) in which postmenopausal women aged at least 50 years with WHO...” PMID 33152284 ↗ Nov 2020746“One hundred fourteen consecutive elderly women with T2-4 N0-1 and estrogen receptor-positive breast cancer were randomly assigned to primary letrozole therapy (2.5 mg daily for...” PMID 16877730 ↗ Aug 2006 “Aromatase inhibitor (anastrozole or exemestane or letrozole) oral daily tablet, or Selective Estrogen Receptor Modulator (SERM) such as tamoxifen oral daily tablet or...” NCT03820830 ↗ “aromatase inhibitors ( letrozole 2.5 mg PO per day or Anastrozole 1 mg PO per day or aromasin 25 mg PO per day) if post-menopausal, if premenopausal leutnising hormone...” NCT04012918 ↗ “This treatment consisted of any aromatase inhibitor (e.g. letrozole or exemestane), administered intravenously in Cohort A Groups daily for either 18 (if 6 doses of WT1...” NCT01220128 ↗ “Options include tamoxifen (20 mg daily), aromatase inhibitors (letrozole 2.5 mg daily, anastrozole 1 mg daily, or exemestane 25 mg daily), or fulvestrant (500 mg...” NCT07708194 ↗ “Aromatase inhibitor of the investigator's choice (letrozole, anastrozole, or exemestane) will be provided orally once daily until unacceptable toxicity, documentation of...” NCT01446159 ↗ “Letrozole is an aromatase inhibitor. This means it blocks the enzyme aromatase (found in the body's muscle, skin, breast and fat), which is used to convert androgens (hormones...” NCT03959891 ↗ “Endocrine therapy is determined by the doctor, including any kind of letrozole, anastrozole, exemestane, fulvestrant, tamoxifen, toremifene, combined with or without drugs or...” NCT03204734 ↗ “Endocrine therapy (physician's choice based on prior administered agent including tamoxifen, exemestane, fulvestrant, anastrozole, or letrozole). Endocrine therapy must be...” NCT03184090 ↗ “Tamoxifen 20 mg daily, or letrozole 2.5 mg daily, or anastrozole 1 mg daily, or exemestane 25 mg daily (male patients will be treated with tamoxifen 20 mg daily) for a total...” NCT03081234 ↗ “They received tablet letrozole 2.5 mg a day for 12 weeks, and the effect of the drug on myoma size and volume and symptomatology was studied along with the adverse effect...” PMID 24103533 ↗ Sep 2013 “Postmenopausal patients: Letrozole (2.5 mg, orally, once daily, for 5 years) or Anastrozole (1 mg, orally, once daily, for 5 years) or Exemestane (25 mg, orally, once daily,...” NCT07153757 ↗ “Subjects will receive standard therapy with an aromatase inhibitor (exemestane, anastrozole, or letrozole), combined with the experimental treatment of abemaciclib and durvalumab” NCT04088032 ↗ “Letrozole 2.5 mg by mouth daily, or anastrozole 1 mg by mouth daily, exemestane 25 mg by mouth daily, tamoxifen 20 mg by mouth daily, for a total duration of at least 60 months.” NCT03078751 ↗ “The physician's choice of endocrine therapy (PCET) is limited to tamoxifen or one of the specified third generation aromatase inhibitors: letrozole, anastrozole, or exemestane.” NCT04961996 ↗ “Clomiphene citrate (Ovumid®, Iran Hormones Company) 25 mg/day with co-treatment of Letrozole (Letrofem®, Iran Hormones Company) 2.5 mg/day are given from cycle day 3 onwards.” NCT02732808 ↗ “Comparison of Clinical Efficacy Between Letrozole + Ribociclib and Fulvestrant + Letrozole + Ribociclib in Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer” NCT05816655 ↗ “Endocrine therapy: letrozole (2.5mg daily), anastrozole (1mg daily), exemestane (25mg daily), tamoxifen (20mg daily) or fulvestrant (intramuscular 500mg every 4 weeks)” NCT06585969 ↗ “OBJECTIVE: To examine the use of the aromatase inhibitor letrozole with FSH for ovarian stimulation in poor responders undergoing ovarian superovulation and IUI.” PMID 11937133 ↗ Apr 2002 “Patients will receive CB-103 capsules orally (QD) in combination with NSAI therapy (letrozole or anastrozole, continuing prior therapy) also orally once daily” NCT04714619 ↗ “aromatase inhibitor (letrozole 2.5mg/d PO, anastrazole 1mg/d PO, or exemestane 25mg/d PO)or Selective Estrogen Receptor Modulator (SERM) (tamoxifen 20mg/d PO)” NCT00240071 ↗ “Lapatinib in combination with paclitaxel, letrozole, capecitabine, capecitabine/oxaliplatin, gemcitabine, docetaxel, trastuzumab, FOLFOX4, or FOLFIRI” NCT00790816 ↗ “Patients will receive one of the aromatase inhibitors either anastrozole 1 mg po daily, letrozole 2.5 mg po daily, or exemestane 25 mg po daily” NCT01484041 ↗ “Aromatase inhibitors(Letrozole/Anastrozole/Exemestane, po, qd, specific dose (letrozole 2.5mg/ day; Anastrozole 1mg/ day, Exemestane 25mg/ day)” NCT05594095 ↗ “Anastrozole (1 mg/day) or letrozole (2.5 mg/day) or fulvestrant (2x250 mg at day 1 and day 15 then every 4 weeks after the first injection)” NCT05041842 ↗ “Aromatase Inhibitor ( Anastrozole 1 mg, Letrozole 2.5 mg or exemestane 25 mg orally every 24 hours on Days 1 to 28 of a 28-day cycle)” NCT05362760 ↗ “Women with ER-positive tumors also received letrozole (plus a luteinizing hormone-releasing hormone [LHRH] agonist if premenopausal).” PMID 23569315 ↗ Apr 2013 “The investigator chose an aromatase inhibitor (either anastrozole, letrozole or exemestane 1 mg/2.5 mg/25 mg), once daily, oral.” NCT03910712 ↗ “The investigator chose an aromatase inhibitor (either anastrozole, letrozole or exemestane 1 mg/2.5 mg/25 mg), once daily, oral.” NCT04088110 ↗ “The AIs the Investigator could choose from were anastrozole, exemestane, and letrozole and dosing was per product information.” NCT02213042 ↗ “Includes anastrozole 1 mg/day, letrozole 2.5 mg/day, or exemestane 25 mg/day, administered orally once daily for 4 cycles.” NCT07618923 ↗ “["Letrozole","Anastrozole","Exemestane","Tamoxifen","Leuprolide, or other LHRH agonist (per investigator discretion)"]” NCT04569747 ↗ “Letrozole is administered orally at 2.5 mg once daily from Day 2 to Day 5 of the menstrual cycle (5 consecutive days).” NCT07296614 ↗ “Aromatase inhibitor (either letrozole, anastrozole, or exemestane) of investigator's choice given by mouth once daily” NCT01160211 ↗ “drug letrozole in step up dose works better to treat anovulation in infertile women with polycystic ovary syndrome.” NCT07143682 ↗ “The hormone therapy will be either letrozole by mouth once a day at home, or fulvestrant as a shot into the muscle.” NCT03519178 ↗ “either Anastrozole 1 mg po daily; Letrozole 2.5 mg po daily, Exemestane 25 mg po daily or Tamoxifen 20 mg po daily” NCT01897441 ↗ “Endocrine therapy including but not limited to fulvestran, tanastrozole, letrozole or exemestane In regular doses” NCT05431504 ↗ “Hemay022 combined with AI (exemestane or letrozole) in the treatment of ER+/HER2+ advanced breast cancer patients” NCT06313983 ↗ “Letrozole 2.5mg, Anastrozole 1mg, Exemestane 25mg, or Fulvestrant 0.5g IM on Days 1, 28 (initial: Days 1, 15, 28)” NCT07610720 ↗ “Tamoxifen, letrozole, anastrozole, exemestane, fulvestrant, etc, selected at the discretion of the investigator.” NCT05983107 ↗ “The endocrine therapy used for the NET in this study will be anastrozole, letrozole, exemestane, or tamoxifen.” NCT07483307 ↗ “Letrozole, 2.5 mg, will be orally administered once a day in continuous daily dosing together with PD-0332991.” NCT01684215 ↗ “hormone receptor-positive patients were additionally given letrozole (2·5 mg per day orally; if menopausal)” PMID 28238593 ↗ Feb 2017 “physician's choice of endocrine therapy (ET) including fulvestrant, letrozole, anastrozole, and exemestane” NCT06486883 ↗ “Non-steroidal aromatase inhibitor (letrozole or anastrozole, at the discretion of the treating physician)” NCT03425838 ↗ “Investigators choose endocrine therapy including Letrozole, Anastrozole, Exemestane, and Fulvestrant.” NCT06447623 ↗ “Investigators choose endocrine therapy including Letrozole, Anastrozole, Exemestane, and Fulvestrant.” NCT05949541 ↗ “Clomiphene Citrate Plus HPuFSH Versus Letrozole Plus HPuFSH in Clomid Resistant Infertile PCOS Women” NCT01793038 ↗ “All patients will receive the standard of care treatment ie Palbociclib + letrozole for 24-26 weeks” NCT03870919 ↗ “Tamoxifen or aromatase inhibitors (Anastrozole, Letrozole, or Exemestane) combined with trastuzumab” NCT01950182 ↗ “Leucogen combined with Ribociclib (Kisqali®) and Endocrine Therapy (e.g., Letrozole, Anastrozol)” NCT07380646 ↗ “Either Letrozole, Anastrozole, Exemestane or Fulvestrant in combination with CDK 4/6-inhibitor” NCT06044623 ↗ “premenopausal: tamoxifen or toremifene; postmenopausal: letrozole or anastrozole or exemestane” NCT04383275 ↗ “Endocrine Therapy: Tamoxifen 20mg, Letrozole 2.5mg, Anastrozole 1mg, or Exemestane 25mg PO qd” NCT02040857 ↗ “Endocrine Therapy: Exemestane (Aromasin®), Letrozole (Femara®), or Anastrozole (Arimidex®)” NCT03846583 ↗ “Letrozole (2.5mg) will be given orally daily each cycle x 4 cycles. (Other Names: Femara)” NCT03573648 ↗ “Oral letrozole: 7.5 mg/day during the first 5 days of the controlled ovarian stimulation.” NCT02448459 ↗ “Oral letrozole: 7.5 mg/day during the first 5 days of the controlled ovarian stimulation.” NCT02288143 ↗ “Letrozole 2.5 mg daily p.o. for five 21-day cycles (to be continued until surgery).” NCT02411344 ↗ “Letrozole priming before mTOP is used as an alternative to the use of mifepristone.” NCT05341817 ↗ “letrozole oral 2·5 mg/day, anastrozole oral 1 mg/day, or exemestane oral 5 mg/day” NCT07400523 ↗ “Letrozole is formulated as tablets of 2.5 mg strength for oral administration.” NCT02511639 ↗ “Letrozole: 2.5 mg orally once daily, with a 4-week continuous treatment cycle.” NCT07000344 ↗ “Anastrozole or Exemestane or Letrozole administered orally (physician choice)” NCT04188548 ↗ “Endocrine therapy: aromatase inhibitors (anastrozole, letrozole, exemestane)” NCT01619111 ↗ “NSAI: Anastrozole 1mg, 1 time /d, oral or Letrozole: 2.5mg, 1 time /d, oral” NCT06375707 ↗ “Letrozole has been tried for ovarian stimulation for assisted reproduction.” NCT02429999 ↗ “Letrozole 2.5 mg/day will be given from cycle day 3 onwards for only 5 days” NCT06928844 ↗ “Post-menopausal women will receive letrozole 2.5 mg QD in 28-day cycles.” NCT03969121 ↗ “combined with an aromatase inhibitor (letrozole/anastrozole/exemestane)” NCT06970912 ↗ “Anastrozole 1 mg, letrozole 2.5 mg, or exemestane 25 mg by mouth daily” NCT06218303 ↗ “Letrozole: 2.5 mg once daily on a continuous scheme (tablets, per os)” NCT03079011 ↗ “Anastrozole 1mg/day p.o,Exemestane 25mg/day,Letrozole 2.5mg/day p.o.” NCT01924078 ↗ “* Letrozole: 2.5 mg, orally, once daily (continuous), every 28 days” NCT05861830 ↗ “Chidamide+ exemestane/Fulvestrant/Letrozole/Anastrozole/Tamoxifen” NCT05890287 ↗ “Letrozole or anastrozole administered orally (physician choice)” NCT04707196 ↗ “ANASTRAZOLE, ARIMIDEX, AROMASINE, EXEMESTANE, FEMARA, LETROZOLE” NCT03624244 ↗ “Any brand of letrozole, anastrozole or exemestane may be used” NCT02603679 ↗ “letrozole 2.5 mg, anastrozole 1 mg, or exemestane 20 mg PO qd” NCT06145308 ↗ “Letrozole 2.5mg PO daily + Placebo 1 tablet PO 2/day x 1week” NCT01589367 ↗ “Ribociclib 600 mg/day + letrozole during neoadjuvant phase.” NCT05296746 ↗ “letrozole 2.5 mg/day orally or anastrozole 1 mg/day orally” NCT03944434 ↗ “Letrozole tablets ：Orally, 2.5mg once a day; 28 days/cycle” NCT05744687 ↗ “Dalpiciclib combined with Letrozole,28 days as one cycle.” NCT05512780 ↗ “Letrozole, anastrozole as prescribed per standard of care” NCT04352777 ↗ “Letrozole: 2.5 mg/day on a continuous dosing schedule” NCT03778931 ↗ “Endocrine therapy (letrozole/anastrozole/exemestane)” NCT07005557 ↗ “tamoxifen, Letrozole, Anastrazole, Exemestane, etc.” NCT04023292 ↗ “Endocrine therapy alone (letrozole or fulvestrant)” NCT03809988 ↗ “Dalpiciclib combined with letrozole or anastrozole” NCT05640778 ↗ “Letrozole selected by the doctor: 2.5mg, oral Q24H” NCT05969184 ↗ “2.5 mg of letrozole tablet by mouth once daily or” NCT06369285 ↗ “Letrozole 2,5 mg daily or Anastrozole 1 mg daily” NCT04227327 ↗ “Letrozole, Recombinant FSH, GnRH antagonist” NCT04356105 ↗ “* AI: Anastrozole, Letrozole or Exemestane” NCT05826964 ↗ “Letrozole tablets：Administered by oral” NCT05872347 ↗ “Letrozole tablets：Administered by oral” NCT05860465 ↗ “Letrozole, given per os, 2.5 mg daily” NCT05297617 ↗ “anastrozole, letrozole, or exemestane” NCT05894239 ↗ “Letrozole: daily oral dose of 2.5 mg.” NCT02448420 ↗ “Létrozole 2.5 mg/day during 5 years” NCT01127295 ↗ “Letrozole, 2.5mg, orally once daily” NCT05411380 ↗ “Letrozole, 2.5mg, orally once daily” NCT02767661 ↗ “Fermara® (letrozole) 2.5 mg/day PO” NCT00828854 ↗ “Letrozole 2.5mg once a day orally” NCT02910050 ↗ “Letrozole: 2.5mg, 1 time /d, oral” NCT06656624 ↗ “letrozole (2.5 mg every day)” PMID 30106636 ↗ Aug 2018 “oral letrozole 2.5 mg daily” NCT04215003 ↗ “Letrozole 2.5mg once daily” NCT07527806 ↗ “Letrozole or anastrozole” NCT07616453 ↗ “Letrozole or anastrozole” NCT07616427 ↗ “Letrozole 2.5mg per day” NCT06176534 ↗ “Letrozole (2.5mg po qd)” NCT05885776 ↗ “letrozole or exemestane” NCT01654185 ↗ “Letrozole (2.5mg, qd).” NCT05429684 ↗ “ribociclib + letrozole” NCT03050398 ↗ “letrozole (Femara®)” NCT00508586 ↗ “Femara (Letrozole)” NCT01248416 ↗ “Drug: Letrozole” NCT04603183 ↗ “Drug: Letrozole” NCT06650748 ↗ “Letrozole” NCT04341545 ↗ “Letrozole” NCT05512780 ↗ “Letrozole” NCT02995772 ↗ “Letrozole” NCT07596212 ↗ “letrozole” NCT03321981 ↗ “Letrozole” NCT00740194 ↗ “Letrozole” NCT06810492 ↗ “Letrozole” NCT03948568 ↗ |
| Known as | Brand name Femar | “Brand name Femar” NCT01615211 ↗ |
| Known as | CGS 20267 | “Letrozole is a chemical compound, CGS 20267 which is a third-generation, nonsteroidal aromatase inhibitor.” NCT06367712 ↗1“Letrozole, or CGS 20267, is an oral non-steroidal type II aromatase inhibitor.” NCT04619914 ↗ |
| Known as | femar | “24 weeks of treatment with either tablet letrozole (femar®) initial dose of 2.5 mg each day versus tablet placebo.” NCT05205837 ↗ |
| Known as | Femar, letrozol, Novartis Healthcare | “Femar®, letrozol, Novartis Healthcare” NCT00935558 ↗ |
| Known as | Femara | “The purpose of this study is to determine whether the first line combination hormonal therapy of an experimental drug, atamestane, plus an FDA-approved drug, toremifene...” NCT00044291 ↗38“Based on the results from this trial, the aromatase inhibitor letrozole (Femara) is currently recommended as a part of standard adjuvant therapy for postmenopausal women with...” PMID 17912636 ↗ Oct 2007 “In the letrozole group, withdrawal bleeding was achieved using 10 mg of dydrogesterone tablets for 10 days before stimulation, then 2.5 mg of letrozole oral tablets (Femara;...” NCT00956267 ↗ “The purpose of this study is to evaluate the objective response rate of a combination of letrozole (Femara) and bevacizumab (Avastin) given preoperatively to postmenopausal...” NCT00461773 ↗ “The purpose of the study is to investigate the effects (good and bad) that the combination of the drugs letrozole (also called Femara™) and trastuzumab (also called Herceptin®)...” NCT00134680 ↗ “letrozole (femara, Novartis) orally in a dose of 2.5 mg daily, on day 2 of cycle for 5 days and gonadotropins (300-450 IU) IM start on cycle day 3. then the dose modulated...” NCT05166668 ↗ “Letrozole (trade name: Femara®; Novartis Pharma Schweiz AG, Switzerland; imported drug license No. H20140149): 2.5 mg/table, 1 table by mouth once a day, continuously for a...” NCT04047758 ↗ “Group 2 will receive Letrozole (Femara®, Novartis, Switzerland) 2.5mg twice daily for 5 days starting from the 3rd day of menstruation or progesterone withdrawal bleeding.” NCT02304107 ↗ “Group 1 will receive Letrozole (Femara®, Novartis, Switzerland) 2.5mg twice daily for 5 days starting from the 3rd day of menstruation or progesterone withdrawal bleeding” NCT02305693 ↗ “Letrozole, sold under the brand name Femara among others, is an aromatase inhibitor which is used in the treatment of hormonally-responsive breast cancer after surgery.” NCT03901170 ↗ “This is a randomized phase II study of letrozole (Femara) administered 2.5 mg orally daily to patients with newly diagnosed clinical stage I and II LMS.” NCT05649956 ↗ “Patients in the MTX + letrozole group received letrozole tablets (Femara 2.5 mg) once daily for ten days starting from the day of MTX administration.” NCT06504082 ↗ “Letrozole oral tablets (Femara 2.5 mg tablet; Novartis Pharma Services, Switzerland) 2.5 mg tab twice daily for 5 days from cycle day 3.” NCT02739516 ↗ “Letrozole (Femara; Novertis pharma AG, Basle, Switzerland) is administered starting on cycle day one for 8 consecutive days .” NCT01219153 ↗ “Letrozole (Femara; Novertis pharma AG, Basle, Switzerland) is administered starting on cycle day one for 8 consecutive days .” NCT04268927 ↗ “the single agent FDA-approved aromatase inhibitor letrozole (Femara®) for the treatment of advanced breast cancer.” NCT00267553 ↗ “Letrozole (Femara; Novartis pharma AG, Basle, Switzerland) 2.5mg /day is administered from cycle day 1 to 9” NCT01232075 ↗ “Letrozol (Femara, Novartis) at a dose of 2.5mg twice daily starting from day 3 of the cycle for 5 days.” NCT05362799 ↗ “Group A received oral letrozole (2.5 mg/day, Femara, Novartis PharmaServices, Basel, Switzerland)” NCT01218581 ↗ “Endocrine Therapy: Exemestane (Aromasin®), Letrozole (Femara®), or Anastrozole (Arimidex®)” NCT03846583 ↗ “All patients start standard therapy with oral letrozole (Femara), day 1 of the study.” NCT04563507 ↗ “All patients start standard therapy with oral letrozole (Femara), day 1 of the study.” NCT04220476 ↗ “5 mg daily (Femara®, Novartis Pharmaceuticals Corporation, East Hanover, NJ )” NCT01999569 ↗ “letrozole 2.5mg (Femara; Novartis Pharma Services, Basel, Switzerland)” NCT04069117 ↗ “Letrozole (Femara; Novartis, East Hanover, NJ) at a dose of 5 mg/day” NCT02293668 ↗ “letrozole (Femara; Novartis pharma AG, Basle, Switzerland)” NCT04619914 ↗ “Letrozole tablets (Femara; Novartis Pharma, Switzerland)” NCT00911313 ↗ “standard oral daily tablet of letrozole (Femara®)” NCT07401381 ↗ “Patients receive oral letrozole (Femara) daily.” NCT00014638 ↗ “letrozole (Femara®, Novartis New York, NY, USA)” NCT04834791 ↗ “another approved drug, letrozole (Femara®)” NCT00097344 ↗ “Femara® Tablets 2.5 mg” NCT00648063 ↗ “Femara® Tablets 2.5 mg” NCT00648154 ↗ “letrozole (Femara®)” NCT00508586 ↗ “letrozole (Femara)” NCT01082068 ↗ “letrozole (Femara)” NCT00908531 ↗ “Letrozole (Femara)” NCT00138710 ↗ |
| Known as | Femara (Letrozole) | “Femara (Letrozole)” NCT01248416 ↗3“Femara (letrozole)” NCT01897441 ↗ “Femara (Letrozole)” NCT00530868 ↗ “Femara (letrozole)” NCT00240071 ↗ |
| Known as | FemarTM | “Patients entered into this study will be given letrozole (FemarTM) in combination with ribociclib (KisqaliTM) for at least 6 months.” NCT05163106 ↗ |
| Known as | Fermara | “Fermara® (letrozole) 2.5 mg/day PO” NCT00828854 ↗ |
| Known as | LEBE | “single IM injection of Letrozole LEBE 75 mg” NCT06315205 ↗ |
| Known as | LET | “The phase 3 MONALEESA-2 study demonstrated that addition of ribociclib (RIB) to letrozole (LET) significantly improved progression-free survival (PFS) in patients (pts) with...” PMID 29404806 ↗ Feb 20183“The National Cancer Institute of Canada Clinical Trials Group MA.17 trial examined the efficacy of letrozole (LET) started within 3 months of 5 years of adjuvant tamoxifen in...” PMID 18332475 ↗ Mar 2008 “After 24 wks, an aromatase inhibitor, letrozole (LET, 2.5 mg/d oral), will be co-administered with TC for 8 wks to block estrogen synthesis and examine whether T's effects are...” NCT04321551 ↗ “In Phase 2, the same protocol was employed with the addition of an aromatase inhibitor (letrozole, LET) administered daily beginning at week 4 for 2 weeks.” PMID 28187771 ↗ Feb 2017 |
| Known as | Letrofem | “Clomiphene citrate (Ovumid®, Iran Hormones Company) 25 mg/day with co-treatment of Letrozole (Letrofem®, Iran Hormones Company) 2.5 mg/day are given from cycle day 3 onwards.” NCT02732808 ↗ |
| Known as | letrol | “The experimental arm (p1) will be treated with letrozole 5 mg for 10 days. The comparator arm (p2) will receive letrozole 10mg for 5 days (Tab letrol 2.5mg -Renata Pharmaceutical.” NCT07448272 ↗ |
| Known as | Letrozol | “The intervention will include changes in medication (e.g. change from Letrozol to Tamoxifen, treatment for polyneuropathy, osteoporosis).” NCT06120595 ↗5“Patients will be given Letrozol 2.5 mg or Anastrazol1 mg, every 24H and all of them will be given Calcium + Vit D supplement.” NCT03111615 ↗ “4. Letrozol tablets, 2.5 mg x 1 orally” NCT03378297 ↗ “Femar®,letrozol, Novartis Healthcare” NCT00935558 ↗ “Letrozol or Anastrozol or Exemestane” NCT02592083 ↗ |
| Known as | Letrozole (Femara) | “Letrozole (Femara)” NCT06218303 ↗ |
| Known as | Letrozole component of kisqali femara co-pack | ChEMBL registry synonym — accepted as the source's own label CHEMBL1444 ↗ |
| Known as | Letrozole Tablets | “Drug: Letrozole Tablets” NCT04906395 ↗ |
| Known as | Letrozole(Femara, Novartis Pharmaceuticals) | “Letrozole(Femara, Novartis Pharmaceuticals)” NCT02491320 ↗ |
| Known as | LTZ | “Postmenopausal women with untreated stage I-III HR+/HER2-negative breast cancer were randomized (1:1:1) to receive 3 weeks of letrozole (LTZ) 2.5 mg/day, oral mVNB 50 mg 3...” PMID 31533777 ↗ Sep 20191“The use of aromatase inhibitor, letrozole (LTZ), in reproductive medicine started in 2001.” NCT02647424 ↗ |
| Known as | NSC-759652 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1444 ↗ |
| Action | Inhibit | “Aromatase inhibitors work by inhibiting the action of the enzyme aromatase, which converts androgens into estrogens by a process called aromatization.” NCT00001521 ↗ |
| Modality | Other / unclassified | “the aromatase inhibitor letrozole” PMID 16145047 ↗ Sep 2005 |
| Route | Oral | “letrozole - 1.5mg/m\^2 body surface area orally” NCT00001521 ↗ |
| Target | CYP19 | “Letrozole is a potent and highly selective third generation aromatase inhibitor that was developed in the early 1990's. Aromatase is an enzyme of the cytochrome P-450...” NCT01035099 ↗ |